Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
ADC Therapeutics S.A.

ADC Therapeutics S.A. (ADCT) Stock Overview

Explore ADC Therapeutics S.A.’s financial performance, market position, analyst ratings, and future outlook.

ADCT●NYSE
HealthcareBiotechnology
$1.51
$0.08(5.03%)
U.S. Market is Open · 13:35

ADC Therapeutics S.A. (ADCT)

Meyka AI Score

Z

Key Financials

Market Cap206.2M
P/E Ratio-2.37
EPS (TTM)$-0.66
ROE0.45%
Fundamental Analysis

AI Price Forecasts

1 Month$1.67
3 Months$0.00
1 Year Target$2.04

ADCT Stock Analysis & Investment Overview (NYSE)

Our AI-powered analysis of ADC Therapeutics S.A. (NYSE: ADCT) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, ADC Therapeutics S.A.'s NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ADCT on the NYSE shows an RSI of 58.69, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $2.04 for the NYSE listing.

Key metrics behind ADC Therapeutics S.A.'s NYSE-traded stock include a P/E ratio of -2.37 and a market capitalization of 206.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ADCT on the NYSE.

Price Performance (NYSE: ADCT)

1-Day Change
1.57%
5-Day Change
2.22%
1-Month Change
28.17%
3-Month Change
45.50%
6-Month Change
-57.16%
Year-to-Date (YTD) Change
-54.25%
1-Year Change
-63.54%
3-Year Change
129.70%
5-Year Change
-94.38%
All-Time (Max) Change
-94.55%

Contact Information

https://www.adctherapeutics.com
41 21 653 02 00
Biopole, Epalinges, VD, 1066

Company Facts

1,910 Employees
IPO DateMay 18, 2020
CountryCH
Actively Trading

Frequently Asked Questions